NASDAQ: CLDX
Celldex Therapeutics Inc Stock Ownership - Who owns Celldex Therapeutics?

Insider buying vs selling

Have Celldex Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Anthony S. MarucciPRESIDENT CEO2024-11-1111,500$26.82
$308.43kBuy

1 of 1

CLDX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CLDX insiders and whales buy or sell their stock.

CLDX Shareholders

What type of owners hold Celldex Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Wellington Management Group LLP12.58%8,354,151$177.61MInstitution
Thomas S. Paluck11.50%7,632,346$162.26MInsider
Kynam Capital Management LP9.79%6,500,000$138.19MInstitution
Blackrock Inc8.32%5,524,132$117.44MInstitution
Fmr LLC8.10%5,380,091$114.38MInstitution
Vanguard Group Inc5.87%3,898,435$82.88MInstitution
Eventide Asset Management LLC5.66%3,754,793$79.83MInstitution
Price T Rowe Associates Inc5.14%3,410,499$72.51MInstitution
Commodore Capital LP4.82%3,200,000$68.03MInstitution
Bellevue Group Ag4.63%3,071,615$65.30MInstitution

1 of 3

CLDX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CLDX85.27%14.73%Net Buying
OCUL79.09%20.91%Net SellingNet Selling
VERA66.33%33.67%Net Selling
INVA57.75%42.25%Net SellingNet Selling
MESO0.33%0.00%

Celldex Therapeutics Stock Ownership FAQ

Who owns Celldex Therapeutics?

Celldex Therapeutics (NASDAQ: CLDX) is owned by 110.90% institutional shareholders, 19.16% Celldex Therapeutics insiders, and 0.00% retail investors. Thomas S. Paluck is the largest individual Celldex Therapeutics shareholder, owning 7.63M shares representing 11.50% of the company. Thomas S. Paluck's Celldex Therapeutics shares are currently valued at $162.26M.

If you're new to stock investing, here's how to buy Celldex Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.